Potassium [2-[3-Bromo-5-[(5-Carbamoyl-4-Cyclopropyl-2-Ethylimidazol-1-Yl)Methyl]-1-Benzofuran-2-Yl]Phenyl]-(Trifluoromethylsulfonyl) Azanide

CAS : 146613-90-3

Ref. 3D-FP103854

Informations sur le produit

• Nom: Potassium [2-[3-Bromo-5-[(5-Carbamoyl-4-Cyclopropyl-2-Ethylimidazol-1-Yl)Methyl]-1-Benzofuran-2-Yl]Phenyl]-(Trifluoromethylsulfonyl) Azanide
• Synonymes: Saprisartan potassium [USAN], 1-((3-Bromo-2-(o-(1,1,1-(trifluoromethanesulfonamido)phenyl)-5-benzofuranyl)methyl)-4-cyclopropyl-2-ethylimidazole-5-carboxamide, monopotassium salt, 1H-Imidazole-5-carboxamide, 1-((3-bromo-2-(2-(((trifluoromethyl)sulfonyl)amino)phenyl-5-benzofuranyl)methyl)-4-cyclopropyl-2-ethyl-, monopotassium salt, Gr 138950C, potassium (2-{3-bromo-5-[(5-carbamoyl-4-cyclopropyl-2-ethyl-1H-imidazol-1-yl)methyl]-1-benzofuran-2-yl}phenyl)[(trifluoromethyl)sulfonyl]azanide, Saprisartan potassium

Description

This compound is a potent and selective agonist for the human mineralocorticoid receptor (hMR). It increases the serum concentration of cortisol, which is an anti-inflammatory hormone. This agent has been shown to increase systolic pressure in humans and has been used as a research tool in the study of congestive heart failure. The nasal drug inhibits the activation of the inflammatory response by inhibiting histamine release from mast cells. Potassium [2-[3-Bromo-5-[(5-carbamoyl-4-cyclopropyl-2-ethylimidazol-1-yl)methyl]-1-benzofuran-2-yl]phenyl]-(trifluoromethylsulfonyl) azanide (CGP7930) has also been shown to be effective at increasing glomerular filtration rate and diastolic blood pressure.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 649.52 g/mol
• Formule: C₂₅H₂₁BrF₃KN₄O₄S
• Degré de pureté: Min. 95%